Shots: The US FDA BT’s designation is based on P-II study assessing the impact of Orencia on the prevention of severe acute GvHD when added to a standard GvHD prophylactic […]readmore
Tags : Orencia
Shots: The P-IV Early AMPLE mechanistic study results involve assessing of Orencia (125 mg, SC) vs adalimumab (40mg, SC) on a background of MTX in 80 patients in a ratio […]readmore